Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: A retrospective, single-institution study

Anti-Cancer Drugs

Volumn 25, Issue 6, 2014, Pages 723-728

  Hassler, Marco R ^a   Ackerl, Michael ^a   Flechl, Birgit ^a   Sax, Cornelia ^a   Wöhrer, Adelheid ^a,b   Widhalm, Georg ^a   Dieckmann, Karin ^a   Hainfellner, Johannes ^a,b   Preusser, Matthias ^a   Marosi, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anaplastic astrocytoma; Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Glioblastoma; High grade glioma; Sorafenib

Indexed keywords

DACARBAZINE; ERLOTINIB; FOTEMUSTINE; IMATINIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; BRAIN HEMORRHAGE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; GLIOMA; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MALE; MONOTHERAPY; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901487106     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000077     Document Type: Review

References (23)

1. Wö hrer A,Waldhö r T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, et al. The Austrian Brain Tumour Registry: A cooperative way to establish a population-based brain tumour registry. J Neurooncol 2009; 95:401-411.
2. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: Emerging molecular targets for treating glioblastoma. Neuro Oncol 2011; 13:566-579.
3. Cea V, Sala C, Verpelli C. Antiangiogenic therapy for glioma. J Signal Transduction 2012; 2012:483040.
4. Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Sorafenib exerts anti-glioma activity in vitro and in vivo. Neurosci Lett 2010; 478:165-170.
5. Wilhelm SM, Carter C, Tang L,Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
6. Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, et al. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Mol Cancer Ther 2010; 9:953-962.
7. Jane EP, Premkumar DR, Pollack IF. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther 2006; 319:1070-1080.
8. DuW, Zhou JR,Wang DL, Gong K, Zhang QJ. Vitamin K1 enhances sorafenibinduced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol 2012; 10:60.
9. Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, et al. Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma. Neuro Oncol 2011; 13:1324-1330.
10. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010; 28:1963-1972.
11. Kunnakkat S, Narayana A. Bevacizumab in the treatment of high-grade gliomas: An overview. Angiogenesis 2011; 14:423-430.
12. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 28:4733-4740.
13. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.
14. Nabors LB, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Supko J, et al. A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401) [ASCO Meeting Abstracts]. J Clin Oncol 2007; 25:2058.
15. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011; 101:57-66.
16. Zustovich F, Landi L, Lombardi G, Porta C, Galli L, Fontana A, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: A phase II study. Anticancer Res 2013; 33:3487-3494.
17. Prados M, Gilbert M, Kuhn J, Lamborn K, Cloughesy T, Lieberman F, et al. Phase I/II study of sorafenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02) [ASCO Meeting Abstracts]. J Clin Oncol 2009; 27:2005.
18. Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, et al. NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol 2013; 15:490-496.
19. Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, et al. NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study [ASCO Meeting Abstracts]. J Clin Oncol 2011; 29:2033.
20. Jaeckle KA, Schiff D, Anderson SK, Galanis E, Stella PJ, Flynn PJ, et al. NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/ temozolomide (TMZ) and VEGF inhibitors (VEGFi) [ASCO Meeting Abstracts]. J Clin Oncol 2013; 31:2014.
21. Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02) [ASCO Meeting Abstracts]. J Clin Oncol 2009; 27:2006.
22. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 2012; 14:1511-1518.
23. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and metaanalysis. Lancet Oncol 2008; 9:117-123..